Steven Nissen, M.D.

Stories

One-time CRISPR therapy keeps cholesterol lower for a full year in early trial

As of September 2026: Senior investigator on the CTX310 program

A single infusion of a CRISPR gene-editing therapy kept LDL cholesterol about 52% lower and triglycerides about 48% lower for a full year in a 15-patient trial. It is the longest durability data yet for in vivo CRISPR in heart disease.

Updated Sep 27